SSR3 and glioma: We recently reported endoplasmic reticulum translocon complex protein SSR3 as a predictive biomarker for glioma and breast cancer susceptibility to this drug.22 In a companion manuscript (Dmello et al., submitted to Neuro-Oncology Advances), we report an analysis of available tumor samples from this phase II trial (NCT01967810), where we evaluated the correlation with baseline SSR3 expression with OS on this cohort.